34.57
전일 마감가:
$36.68
열려 있는:
$35.8
하루 거래량:
2.94M
Relative Volume:
1.15
시가총액:
$10.05B
수익:
$2.08B
순이익/손실:
$466.92M
주가수익비율:
22.16
EPS:
1.56
순현금흐름:
$404.94M
1주 성능:
-5.80%
1개월 성능:
-9.72%
6개월 성능:
+29.67%
1년 성능:
+47.17%
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
EXEL
Exelixis Inc
|
34.57 | 10.05B | 2.08B | 466.92M | 404.94M | 1.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
2024-09-19 | 개시 | UBS | Neutral |
2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2023-12-19 | 개시 | BTIG Research | Buy |
2023-12-15 | 개시 | Citigroup | Buy |
2023-09-26 | 개시 | H.C. Wainwright | Buy |
2023-08-22 | 재확인 | Oppenheimer | Outperform |
2023-08-08 | 개시 | SVB Securities | Market Perform |
2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
2023-05-10 | 재개 | Piper Sandler | Overweight |
2023-03-09 | 개시 | Wells Fargo | Overweight |
2023-01-26 | 개시 | Credit Suisse | Outperform |
2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
2022-06-24 | 개시 | BMO Capital Markets | Outperform |
2021-11-19 | 개시 | Piper Sandler | Overweight |
2021-11-03 | 재개 | Jefferies | Buy |
2021-10-07 | 개시 | Jefferies | Buy |
2021-08-06 | 재확인 | H.C. Wainwright | Buy |
2021-06-15 | 개시 | H.C. Wainwright | Buy |
2021-05-18 | 재개 | Goldman | Sell |
2021-03-31 | 개시 | Credit Suisse | Outperform |
2021-03-12 | 개시 | Wolfe Research | Outperform |
2020-03-04 | 개시 | Barclays | Overweight |
2020-01-13 | 개시 | SunTrust | Buy |
2019-11-13 | 개시 | BofA/Merrill | Buy |
2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2018-09-17 | 개시 | Goldman | Neutral |
2018-09-10 | 개시 | Morgan Stanley | Underweight |
2018-05-11 | 재확인 | Needham | Buy |
2017-10-17 | 재확인 | Needham | Buy |
2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
2017-10-16 | 재확인 | SunTrust | Buy |
2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
2017-09-12 | 재확인 | Needham | Buy |
2017-07-14 | 개시 | SunTrust | Buy |
2017-03-31 | 개시 | Needham | Buy |
2017-03-16 | 개시 | Oppenheimer | Perform |
2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
2016-11-03 | 개시 | Deutsche Bank | Buy |
2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
The Smartest Biotech Stocks to Buy With $50 - The Motley Fool
FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs - MarketBeat
Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - Insider Monkey
Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
New Age Alpha Advisors LLC Makes New $2.10 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis Launches Special Equity Award Program - TipRanks
(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN
What is Leerink Partnrs' Estimate for Exelixis Q1 Earnings? - MarketBeat
Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN
Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa
FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance
Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail
Exelixis stock holds $40 target post FDA nod - Investing.com
Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa
FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa
Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance
Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - TradingView
Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India
Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India
Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors - Endpoints News
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors - Benzinga
Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET - Yahoo Finance
Citi maintains Buy on Exelixis stock with $45 target By Investing.com - Investing.com Canada
Citi maintains Buy on Exelixis stock with $45 target - Investing.com India
Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down - TradingView
Exelixis wins FDA label expansion for Cabometyx (EXEL:NASDAQ) - Seeking Alpha
Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors - MarketScreener
Exelixis Gets Expanded FDA Approval of Cabometyx in Advanced Neuroendocrine Tumors - MarketWatch
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors - MarketScreener
FDA approves new treatment for advanced neuroendocrine tumors - Investing.com
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Joplin Globe
(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
FDA Approves Cabozantinib For Adults And Pediatric Patients 12 Years Of Age And Older With pNET And epNET - MarketScreener
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 - BioSpace
Looking Into Exelixis's Recent Short Interest - Benzinga
Exelixis (NASDAQ:EXEL) shareholders have earned a 16% CAGR over the last five years - simplywall.st
Biotech Leader Exelixis Eyes Buy Point In Today's Stock Market Rally - MSN
Interesting EXEL Put And Call Options For November 21st - Nasdaq
Learn to Evaluate (EXEL) using the Charts - Stock Traders Daily
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Exelixis Growth Continues with Big Money Boosts - Yahoo Finance
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA - Business Wire
Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):